ROS1 and non-small cell lung carcinoma: A bias-corrected targeted NGS detected a broad range of actionable genomic alterations in the plasma, including ALK, ROS1, and RET rearrangements, HER2 insertions, and MET amplification in advanced NSCLC, with 100% specificity [34].